| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Y Smith, J Z Kieva. Anatomy of the dopamine system in the basal ganglia. Trends in neurosciences. vol 23. issue 10 Suppl. 2001-02-08. PMID:11052217. |
the local dendritic release of dopamine by neurons in the substantia nigra pars compacta and ventral tegmental also influences basal ganglia functions. |
2001-02-08 |
2023-08-12 |
Not clear |
| Y Smith, J Z Kieva. Anatomy of the dopamine system in the basal ganglia. Trends in neurosciences. vol 23. issue 10 Suppl. 2001-02-08. PMID:11052217. |
thus, the long-term belief that the effects of dopamine in the basal ganglia were solely mediated through the nigrostriatal system must be changed to take into account extrastriatal dopaminergic projections and intrastriatal dopaminergic neurons. |
2001-02-08 |
2023-08-12 |
Not clear |
| J R Walters, D N Ruskin, K A Allers, D A Bergstro. Pre- and postsynaptic aspects of dopamine-mediated transmission. Trends in neurosciences. vol 23. issue 10 Suppl. 2001-02-08. PMID:11052219. |
dopamine agonist administration induces changes in firing rate and pattern in basal ganglia nuclei that provide an insight into the role of dopamine in basal ganglia function. |
2001-02-08 |
2023-08-12 |
Not clear |
| D J Brook. PET studies and motor complications in Parkinson's disease. Trends in neurosciences. vol 23. issue 10 Suppl. 2001-02-08. PMID:11052227. |
additional pet studies suggest that loss of striatal dopamine storage capacity along with pulsatile exposure to exogenous l-dopa results in pathologically raised synaptic dopamine levels and deranged basal ganglia opioid transmission.this, rather than altered dopamine receptor binding, then causes inappropriate overactivity of basal ganglia-frontal projections, resulting in breakthrough involuntary movements. |
2001-02-08 |
2023-08-12 |
Not clear |
| T Hashimot. [Pathophysiology of abnormal movements in Parkinson's disease]. Nihon rinsho. Japanese journal of clinical medicine. vol 58. issue 10. 2001-02-01. PMID:11068437. |
major parkinsonian motor symptoms, i.e., bradykinesia, muscular rigidity, and resting tremor, are due to abnormalities in the motor circuit of the basal ganglia caused by loss of nigrostriatal dopamine neurons. |
2001-02-01 |
2023-08-12 |
Not clear |
| J A Obeso, M C Rodriguez-Oroz, M Rodriguez, R Macias, L Alvarez, J Guridi, J Vitek, M R DeLon. Pathophysiologic basis of surgery for Parkinson's disease. Neurology. vol 55. issue 12 Suppl 6. 2001-02-01. PMID:11188978. |
dopamine depletion induces a series of changes in the basal ganglia motor circuit that underlie the origin of the cardinal features of parkinson's disease. |
2001-02-01 |
2023-08-12 |
Not clear |
| F I Tarazi, K Zhang, R J Baldessarin. Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain research. vol 881. issue 1. 2000-12-12. PMID:11033095. |
the findings indicate that nigrostriatal dopamine denervation can selectively enhance ka receptor levels in rat basal ganglia, suggest that ka receptors contribute to the pathophysiology of parkinson's disease, and may suggest innovative treatments. |
2000-12-12 |
2023-08-12 |
rat |
| J Kulisevsk. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs & aging. vol 16. issue 5. 2000-11-13. PMID:10917074. |
instead, it may be a function of the level of dopamine depletion in different parts of the basal ganglia and prefrontal cortex. |
2000-11-13 |
2023-08-12 |
human |
| M G Murer, G Dziewczapolski, P Salin, M Vila, K Y Tseng, M Ruberg, M Rubinstein, M A Kelly, D K Grandy, M J Low, E Hirsch, R Raisman-Vozari, O Gershani. The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice. Neuroscience. vol 99. issue 4. 2000-11-07. PMID:10974427. |
the indirect basal ganglia pathway in dopamine d(2) receptor-deficient mice. |
2000-11-07 |
2023-08-12 |
mouse |
| M G Murer, G Dziewczapolski, P Salin, M Vila, K Y Tseng, M Ruberg, M Rubinstein, M A Kelly, D K Grandy, M J Low, E Hirsch, R Raisman-Vozari, O Gershani. The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice. Neuroscience. vol 99. issue 4. 2000-11-07. PMID:10974427. |
recent pathophysiological models of basal ganglia function in parkinson's disease predict that specific neurochemical changes in the indirect pathway would follow the lack of stimulation of d(2) dopamine receptors. |
2000-11-07 |
2023-08-12 |
mouse |
| M Segaw. Development of the nigrostriatal dopamine neuron and the pathways in the basal ganglia. Brain & development. vol 22 Suppl 1. 2000-11-07. PMID:10984655. |
development of the nigrostriatal dopamine neuron and the pathways in the basal ganglia. |
2000-11-07 |
2023-08-12 |
Not clear |
| M Segaw. Development of the nigrostriatal dopamine neuron and the pathways in the basal ganglia. Brain & development. vol 22 Suppl 1. 2000-11-07. PMID:10984655. |
the nigrostriatal (ns) dopamine (da) neuron and the basal ganglia show marked functional age variation in the first three decades. |
2000-11-07 |
2023-08-12 |
Not clear |
| P Svenningsson, L Gunne, P E Andre. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset. Neuroscience. vol 99. issue 3. 2000-11-07. PMID:11029538. |
the effects of l-dopa probably depend both on a direct activation of supersensitized dopamine receptors by dopamine produced in the few remaining, but hyperactive, dopaminergic nerve terminals and in serotonergic nerve terminals, as well as on indirect actions of l-dopa related to activation of circuitries connecting cerebral cortex and basal ganglia structures. |
2000-11-07 |
2023-08-12 |
marmoset |
| R M Moresco, C Colombo, F Fazio, A Bonfanti, G Lucignani, C Messa, C Gobbo, L Galli, A Del Sole, A Lucca, E Smerald. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. NeuroImage. vol 12. issue 4. 2000-11-01. PMID:10988039. |
drug effect was evaluated in different cortical areas and in the basal ganglia by positron emission tomography (pet) and fluoro-ethyl-spiperone ([(18)f]fesp), an high affinity 5ht(2) serotonin and d(2) dopamine receptors antagonist. |
2000-11-01 |
2023-08-12 |
Not clear |
| R M Moresco, C Colombo, F Fazio, A Bonfanti, G Lucignani, C Messa, C Gobbo, L Galli, A Del Sole, A Lucca, E Smerald. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. NeuroImage. vol 12. issue 4. 2000-11-01. PMID:10988039. |
on the contrary, no significant changes in the in vivo [(18)f]fesp binding were found in the basal ganglia where [(18)f]fesp binds mainly to d(2) dopamine receptors. |
2000-11-01 |
2023-08-12 |
Not clear |
| K C Berridge, J W Aldridg. Super-stereotypy II: enhancement of a complex movement sequence by intraventricular dopamine D1 agonists. Synapse (New York, N.Y.). vol 37. issue 3. 2000-10-06. PMID:10881042. |
our results highlight a role for dopamine d1 receptors, probably within the basal ganglia, in the production of sequential super-stereotypy of complex behavioral patterns. |
2000-10-06 |
2023-08-12 |
rat |
| R W Haley, J L Fleckenstein, W W Marshall, G G McDonald, G L Kramer, F Pett. Effect of basal ganglia injury on central dopamine activity in Gulf War syndrome: correlation of proton magnetic resonance spectroscopy and plasma homovanillic acid levels. Archives of neurology. vol 57. issue 9. 2000-10-05. PMID:10987894. |
effect of basal ganglia injury on central dopamine activity in gulf war syndrome: correlation of proton magnetic resonance spectroscopy and plasma homovanillic acid levels. |
2000-10-05 |
2023-08-12 |
Not clear |
| E M Denovan-Wright, H A Robertso. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience. vol 98. issue 4. 2000-09-27. PMID:10891614. |
as the endogenous cannabinoid receptor agonist, anandimide, has been shown to modulate dopamine neurotransmission within the basal ganglia, the loss of cannabinoid receptors may contribute to the development of motor symptoms or cognitive decline or both seen in huntington's disease patients. |
2000-09-27 |
2023-08-12 |
mouse |
| G L Caporaso, J A Bibb, G L Snyder, C Valle, S Rakhilin, A A Fienberg, H C Hemmings, A C Nairn, P Greengar. Drugs of abuse modulate the phosphorylation of ARPP-21, a cyclic AMP-regulated phosphoprotein enriched in the basal ganglia. Neuropharmacology. vol 39. issue 9. 2000-09-20. PMID:10854908. |
we speculate that arpp-21 might mediate some of the physiologic effects of dopamine and certain drugs of abuse in the basal ganglia. |
2000-09-20 |
2023-08-12 |
mouse |
| M Glass, M Dragunow, R L Faul. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. vol 97. issue 3. 2000-09-14. PMID:10828533. |
the pattern of neurodegeneration in huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and gaba(a) receptor alterations in the human basal ganglia in huntington's disease. |
2000-09-14 |
2023-08-12 |
human |